Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy

Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, and it is a disease of dismal prognosis. While immunotherapy has revolutionized the treatment of various solid tumors, it has achieved little success in PDAC. Hypoxia within the stroma-rich tumor microenvironment i...

Full description

Bibliographic Details
Main Authors: Raefa Abou Khouzam, Jean-Marie Lehn, Hemma Mayr, Pierre-Alain Clavien, Michael Bradley Wallace, Michel Ducreux, Perparim Limani, Salem Chouaib
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
hypoxia
pancreatic cancer
immunotherapy
targeting hypoxia
vascular normalization
ITPP
Online Access:https://www.mdpi.com/2072-6694/15/4/1235

Internet

https://www.mdpi.com/2072-6694/15/4/1235

Similar Items